Ubs Group Ag Cerevel Therapeutics Holdings, Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$38.96 - $42.75 $548,712 - $602,091	-14,084 Reduced 4.61%	291,457 $11.9 Million
Q1 2024 May 13, 2024	BUY	$40.88 - $43.27 $3.57 Million - $3.78 Million	87,421 Added 40.08%	305,541 $12.9 Million
Q4 2023 Feb 09, 2024	BUY	$20.27 - $42.44 $1.83 Million - $3.84 Million	90,463 Added 70.86%	218,120 $9.25 Million
Q3 2023 Nov 09, 2023	BUY	$20.26 - $31.91 $538,895 - $848,774	26,599 Added 26.32%	127,657 $2.79 Million
Q2 2023 Aug 11, 2023	SELL	$23.9 - $35.38 $523,816 - $775,423	-21,917 Reduced 17.82%	101,058 $3.21 Million
Q1 2023 May 12, 2023	BUY	$22.82 - $35.32 $194,814 - $301,526	8,537 Added 7.46%	122,975 $3 Million
Q4 2022 Feb 08, 2023	BUY	$25.35 - $31.96 $2.42 Million - $3.05 Million	95,357 Added 499.75%	114,438 $3.61 Million
Q3 2022 Nov 10, 2022	SELL	$25.5 - $41.42 $850,246 - $1.38 Million	-33,343 Reduced 63.6%	19,081 $539,000
Q2 2022 Aug 10, 2022	BUY	$20.62 - $37.15 $320,207 - $576,902	15,529 Added 42.09%	52,424 $1.39 Million
Q1 2022 May 16, 2022	SELL	$23.5 - $35.38 $4.1 Million - $6.17 Million	-174,487 Reduced 82.55%	36,895 $1.29 Million
Q4 2021 Feb 14, 2022	BUY	$29.21 - $44.64 $5.93 Million - $9.07 Million	203,162 Added 2471.56%	211,382 $6.85 Million
Q3 2021 Nov 15, 2021	BUY	$21.26 - $38.85 $36,567 - $66,822	1,720 Added 26.46%	8,220 $243,000
Q2 2021 Aug 13, 2021	SELL	$12.56 - $29.69 $23,901 - $56,500	-1,903 Reduced 22.65%	6,500 $167,000
Q1 2021 May 12, 2021	SELL	$12.37 - $17.74 $61,466 - $88,150	-4,969 Reduced 37.16%	8,403 $115,000
Q4 2020 Feb 11, 2021	BUY	$9.82 - $18.27 $131,313 - $244,306	13,372 New	13,372 $222,000

Others Institutions Holding CERE

# of Institutions

Shares Held

5.01M

Call Options Held

3.3K

Put Options Held

View Full List

About Cerevel Therapeutics Holdings, Inc.

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

More about CERE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account